# **Supplementary Information**

**Supplementary Methods** 

**Supplementary References** 

## **Supplementary Figures:**

Fig. S1. Strategy to compute the sign of the regulatory interactions.

Fig. S2. Comparison of the precision in the identification of gene-disease interactions between eQTL and RNetDys.

Fig. S3. Cell (sub)type specific regulatory impairment in PD.

Fig. S4. Cell (sub)type specific regulatory impairment in EPI.

Fig. S5. Cell type specific impairment in T1D.

Fig. S6. Cell type specific impairment in T2D.

Fig. S7. Distribution of the outdegree ratio for specific TFs across cell (sub)types.

Fig. S8. Threshold selection to define accessibility of promoter regions.

## **Supplementary Tables:**

Table S1. Single cell datasets used for validation and comparison.

Table S2. Collected datasets to generate healthy cell (sub)type GRNs.

Table S3. Matching of the scRNA-seq and scATAC-seq brain datasets.

Table S4. Literature-based validation of the predicted impaired regulatory interactions.

## **RNetDys workflow**

## Cell (sub)type and state specific GRN inference

The GRN inference part of RNetDys relies on the combination of multi-OMICS data including single cell datasets (scRNA-seq and scATAC-seq) and prior-knowledge (ChIP-seq and GeneHancer). First, a quality control is performed on the scRNA-seq and scATAC-seq in which any rows (gene or peaks) or columns (cells) having a sum of zero is removed from further analyses.

Then, the following steps are computed to infer the cell (sub)type or state specific regulatory interactions:

- (1) TF-Genes interactions: First, using the scRNA-seq data, we pre-selected genes conserved at least in 50% of the cells for candidate interactions. Indeed, we consider genes expressed in the majority of the cells to be representative in the specific cell (sub)type. In addition, from the scATAC-seq peaks matrix, coordinates are extracted to identify accessible promoter regions. Notably, a gene promoter region was identified from the ChIP-seq collected from ChIP-Atlas (Oki et al., 2018), using HOMER (Heinz et al., 2010) annotations by filtering peaks related to gene types annotated as protein coding, and defined as a region between 1500bp upstream and 500bp downstream. A promoter is considered as accessible if its gene has been considered as expressed (conserved at least in 50% of the cells) and at least one ATAC peak is overlapping. The overlap between promoter regions and the peaks coordinates was performed using BEDTools (Quinlan and Hall, 2010) with the parameter -f = 0.48 in reciprocal mode (-r). We identified the overlap parameter f = 0.48 as being the one with the highest probability to capture a real cell (sub)type accessible promoter region. The procedure used to select 0.48 is described in "Identification of accessible gene promoter regions" of the Supplementary Methods. Finally, the resulting overlapping between promoter regions and chromatin accessibility allow us to predict the cell (sub)type or state specific TF-Genes interactions.
- (2) Enhancer-Promoters interactions: First, we identified open enhancer regions by intersecting the ChIP-seq data and the scATAC peaks coordinates using BEDTools with the parameter -F 1.0 selecting open enhancer if 100% of the region is accessible. Then, we splitted the scATAC peaks matrix such that one matrix contains accessible promoter regions, obtained previously, and the other one accessible enhancer regions. We then computed the correlation between the two matrices, using the Pearson metric with the propagate R package (Andrej-Nikolai Spiess, 2018) that requires few computational resources to perform correlation of large matrices. Z-scores and corresponding p-values using a one-sided test on a normal distribution is performed for each pairwise correlation generated. Then, a Benjamini-Hochberg multiple test correction was performed on the computed p-values. The network was generated by selecting enhancer regions as sources, and promoter regions as targets, filtering the edges such as p-adjusted value < 0.05 and</p>

keeping promoters for which genes were found in the TF-Genes network. Notably, only positive correlation could be find as being significant as a negative correlation between accessibility peaks translate an absence of interaction between enhancers and promoters. We then retrieved the genes corresponding to the promoter regions using the ChIP-seq data used by RNetDys. Finally, the enhancer-promoter correlation network is intersected with all GeneHancer (Fishilevich et al., 2017) reported connections.

(3) <u>TF-Enhancers interactions</u>: First, enhancers present in the Enhancer-Promoter network are selected. They are then intersected with the ChIP-seq data, using bedtool and -F 1.0, such as if 100% of the TF peak fell inside the enhancer region, then this TF is interacting with the enhancer.

All the interactions of the comprehensive network were then signed based on the scRNA-seq dataset using the Pearson correlation metric between TFs and genes. For TF-Genes interactions, the correlation value defined the sign of the interactions such as positive correlations are most likely activation whereas negative ones are most likely repression. Then, signs for Enhancer-Promoter interactions were determined by computing the sum of correlation values for the TFs binding to the enhancer regulating the specific promoter/gene with the correlation corresponding to the TF-gene relationship (Figure S1) such as:

$$corV_{E_a \to G_b} = \sum_{x} corV_{TF_x \to G_b}$$

With corV: correlation value, TF: transcription factor, E: enhancer, G: gene

Finally, signs for TF-Enhancers were computed by summing, for each TF binding of the enhancer, the TF-genes relationship correlation values for each gene/promoter regulated by the enhancer (Figure S1) such as:

$$corV_{TF_a \to E_b} = \sum_{x} corV_{TF_a \to G_x}$$

With corV: correlation value, TF: transcription factor, E: enhancer, G: gene

#### Contextualization towards the disease state to identify candidate impaired interactions

Based on a GRN from a healthy cell (sub)type or state, the regulatory network was contextualized towards the disease condition of interest based on a list of SNPs. First, promoter regions coordinate for which a TF binding site has been identified is retrieved from the ChIP-seq data. Then, provided SNPs are mapped to these regions and enhancer regions of the GRN using bedtool under the condition that the SNP falls exactly inside one of the regions (parameter -F 1). This step allows the identification of candidate impaired regulatory interactions, including TF-genes and enhancerpromoters, for the specific cell (sub)type. Finally, a TF binding affinity analysis is performed on the SNP impacted regions. The fasta sequences for impacted enhancer and promoter regions were retrieved from genome.ucsc.edu accordingly with the genome assembly, 50bp upstream and downstream were selected from the SNP position and the SNP [ref/alt] alleles were added to the sequence. Then, we used PERFECTOS-APE (E. Vorontsov et al., 2015) to perform the TF motif binding affinity analysis for each SNP on each region found to be involved in regulation. Then, using the cell (sub)type specific GRN, TFs that were binding specifically on the impaired promoter or enhancer were retrieved as well as their dysregulated affinity score. Notably, we used PERFECTOS-APE with the following modified parameters: --pvalue-cutoff 0.05 --fold-changecutoff 2. Finally, we ranked the TFs to prioritize the regulators that are impaired due to SNPs and hence are most likely to play a role in the dysregulations observed in the disease condition. The rank of each TF regulator was computed as follow:

$$Rank_{TF} = RE \times \frac{NG}{RE} \times \left( \sum |AI|_{i}^{r} \times \left( MAF_{i}^{r} \times \sum MAF^{r} \right) \right)$$

With RE: number of regulatory elements regulated by the TF, NG: number of downstream genes across RE, AI: binding affinity impairment log2FC, i: SNPs, r: regulatory element.

#### Identification of accessible gene promoter regions

We intersected ChIP-seq peaks related to gene promoter regions with ATAC peaks from scATACseq data to identify accessible cell (sub)type promoter regions using bedtool. In order to define the best threshold to use for the overlapping between the ChIP and ATAC peaks, we collected ChIPseq from ChIP-ATLAS and compiled four human cell line specific ChIP-seq gold standards (BJ, GM12878, H1 ESC and K-562). We then used all the ChIP-seq collected from ChIP-ATLAS (aspecific) and considered a ChIP peak to be a true positive (TP) if it was found in the cell line specific GS and a false positive (FP) if it was not found in the GS. We computed the percentage of overlaps between ATAC peaks and TPs or FPs ChIP-peaks independently. Then, we computed the delta probability distribution such as: ecdf(TPs overlap) - ecdf (FPs overlap), and selected the highest point = 0.48. Indeed, 0.48 corresponded to the reciprocal threshold for which the probability to capture a TP (cell (sub)type specific ChIP peak) was the highest and was used as default by the RNetDys (Figure S8).

#### Generation of the cell (sub)type specific GRNs in healthy condition

We collected scRNA-seq and scATAC-seq data from human pancreas and brain tissues (Table S2). The scRNA-seq datasets were processed using Seurat v4 (Hao et al., 2021) and, the gene expression and peaks matrices for each cell (sub)type were extracted for each tissue using Signac (Stuart et al., 2020). Annotations were used from their original studies for all tissues.

- <u>Pancreas:</u> we performed the peak calling with MACS2 (-q 0.05 --call-summits) for each cell (sub)type and the peak matrices were extracted for the cell (sub)types having a corresponding scRNA-seq matrix by using the FeatureMatrix function provided by Signac. We then used Seurat to extract all the cell (sub)type scRNA-seq matrices.
- Brain: several datasets were collected to match scRNA-seq and scATAC-seq data in order to extract cell (sub)types and states for different brain regions (Table S3). scATAC-seq fragment files were obtained after request to the authors and the general peaks matrix as well as metadata were retrieved from the public repository of their study (Corces et al., 2020). Each brain region-related scATAC-seq cell (sub)types clusters were annotated using Signac and Seurat with their matched scRNA-seq dataset (Table S3), whereas the cell type annotations were kept from the original study (Corces et al., 2020). We performed the peak calling with MACS2 (-q 0.05 --call-summits) for each cell (sub)type in each brain region. The peak matrices were extracted for the cell (sub)types having a corresponding scRNA-seq matrix by using the FeatureMatrix function provided by Signac. We then used Seurat to extract all the cell (sub)type scRNA-seq matrices. First, we processed the frontal cortex data, imputed the dropouts using MAGIC due to the high rate of zeros (van Dijk et al., 2018) and used the annotations provided by the authors to extract the cell (sub)types (Lake et al., 2018). Of note, excitatory subtypes were merged as excitatory neurons and inhibitory ones as inhibitory neurons to match with the scATAC-seq. Then, we extracted

the cell (sub)types of the substantia nigra for healthy patients while keeping the annotations provided by the authors (Smajić et al., 2022).

Each cell (sub)type GRN was generated using the extracted scRNA-seq and scATAC-seq datasets with the GRN inference part of RNetDys using the default parameters.

#### GRN inference benchmarking and comparison to state-of-the-art

We first assessed the performances of RNetDys to capture cell (sub)type specific TF-Gene interactions and compared to state-of-the-art methods including CLR (Zhang et al., 2016), GENIE3 (Huynh-Thu et al., 2010), SCENIC (Aibar et al., 2017), PIDC (Chan et al., 2017) and ppcor (Kim, 2015). All methods were used with default parameters to infer the TF-Genes networks and applied to 20 single cell RNA-seq datasets collected from six human cell lines (A549, Jurkat, K-562, GM12878, H1 ESC, BJ). Of note, only genes expressed at least in 50% of the cells for each scRNA-seq dataset were provided to the methods to be consistent for the comparison with RNetDys. In addition, predicted (un)directed GRNs were formatted to obtain TF-gene networks by filtering the Source (regulator) such that it contains any human TFs or co-TFs reported in Animal TFDB (accessed on the 08/04/2022)(Hu et al., 2019). Notably, due to large computational resources or a running time higher than two days, five networks could not be generated, including scRNA-seq datasets of one K562, one GM12878 and three H1-ESCs. RNetDys was used with default parameters on the 20 scRNA-seq datasets and scATAC-seq datasets retrieved for each of the six human cell lines (Table S1). We benchmarked the inferred networks against cell line specific GS standard networks compiled from the Cistrome database and computed the precision (PPV) and accuracy (F1-score). Of note, more than one network was generated by RNetDys for each scRNA-seq dataset used for other methods, depending on the number of scATAC-seq datasets. We hence computed the median PPV and F1 score over the networks to have one metric by scRNA-seq, as we had for each state-of-the-art method. We then assessed the performances of RNetDys in capturing cell (sub)type specific enhancer-promoter regulatory interactions. State-ofthe-art methods used for the TF-Gene benchmarking did not account for enhancers, as they solely relied on scRNA-seq, and hence we performed a comparison using Cicero (Pliner et al., 2018), a widely used strategy to identify co-accessibility between regulatory regions based on scATACseq. We applied RNetDys on twelve combinations of scRNA-seq and scATAC-seq datasets for three human cell lines (Table S1) for which we could compile reliable cell line specific gold

standard networks from 3DIV database (GM12878, H1 ESC, BJ/IMR90). We used Cicero on the scATAC-seq datasets using default parameters and annotated the enhancer and promoter regions using the ChIP-seq leveraged by RNetDys. Notably, not significance score was provided on the interactions and hence, accordingly with Cicero guideline we selected interactions with a co-accessibility score greater than zero. Finally, we benchmarked the predicted networks against the human cell line specific GS networks to compute the PPV and F1-scores.

### Compilation of the gold standard networks

We compiled two types of GS networks, both directed, to assess the performances and validate the specificity in identifying cell (sub)type specific regulatory interactions:

- <u>TF-Genes GS networks</u>: for each human cell line, we collected high quality ChIP-seq data specific to the cell line from Cistrome (Mei et al., 2017). The highest quality was defined as peak data passing all the quality control available in Cistrome.
- (2) <u>Enhancer-promoter GS networks:</u> for each human cell line, we collected Promoter Capture Hi-C data from 3DIV (Yang et al., 2018) database. We then filtered the GS networks to retain enhancers found in GeneHancer and gene promoter regions defined in the ChIP-seq data retrieved from ChIP-Atlas using BEDTools (Quinlan and Hall, 2010).

#### Cell (sub)type specific regulatory mechanisms impaired in diseases

We performed a general study of cell (sub)type specific impairment in diseases by using priorknowledge SNPs to validate the relevance of the captured interactions. We first collected single nucleotide variants from ClinVar (Landrum et al., 2018) and extracted SNPs such as the SNV was found at least in 1% of the global population (MAF >= 0.01). Of note, MAF scores were retrieved for each SNV using BioMart R package and the 'hsapiens\_snp' dataset. Then, we extracted the SNPs for each disease by selecting the ones that have been reported as being related to the disease in ClinVar and, we performed a systematic extraction using regex with the disease name as pattern. Finally, for each cell (sub)type and each disease, we applied RNetDys using the cell (sub)type GRN and the list of SNPs to capture candidate impaired regulatory interactions, TF binding impairment information and the ranked regulators. Notably, SNPs related to AD were mapped to the brain cortex networks whereas SNPs related to PD were mapped to the midbrain networks.

### **Supplementary References**

Aibar, S. et al. (2017) SCENIC: single-cell regulatory network inference and clustering. Nat Methods, 14, 1083–1086.

Andrej-Nikolai Spiess (2018) R Package 'propagate'.

Chan, T.E. et al. (2017) Gene Regulatory Network Inference from Single-Cell Data Using Multivariate Information Measures. Cell Systems, 5, 251-267.e3.

Corces, M.R. et al. (2020) Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases. Nat Genet, 52, 1158–1168.

van Dijk,D. et al. (2018) Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. Cell, 174, 716-729.e27.

E. Vorontsov,I. et al. (2015) PERFECTOS-APE - Predicting Regulatory Functional Effect of SNPs by Approximate P-value Estimation: In, Proceedings of the International Conference on Bioinformatics Models, Methods and Algorithms. SCITEPRESS - Science and and Technology Publications, Lisbon, Portugal, pp. 102–108.

Fishilevich,S. et al. (2017) GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database, 2017.

Hao, Y. et al. (2021) Integrated analysis of multimodal single-cell data. Cell, 184, 3573-3587.e29.

Heinz, S. et al. (2010) Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. Molecular Cell, 38, 576–589.

Hu,H. et al. (2019) AnimalTFDB 3.0: a comprehensive resource for annotation and prediction of animal transcription factors. Nucleic Acids Research, 47, D33–D38.

Huynh-Thu,V.A. et al. (2010) Inferring Regulatory Networks from Expression Data Using Tree-Based Methods. PLoS ONE, 5, e12776.

Kim,S. (2015) ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients. Communications for Statistical Applications and Methods, 22, 665–674.

Lake, B.B. et al. (2018) Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat Biotechnol, 36, 70–80.

Landrum, M.J. et al. (2018) ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res, 46, D1062–D1067.

Mei,S. et al. (2017) Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res., 45, D658–D662.

Oki,S. et al. (2018) Ch IP -Atlas: a data-mining suite powered by full integration of public Ch IP -seq data. EMBO Rep, 19.

Pliner,H.A. et al. (2018) Cicero Predicts cis-Regulatory DNA Interactions from Single-Cell Chromatin Accessibility Data. Mol Cell, 71, 858-871.e8.

Quinlan,A.R. and Hall,I.M. (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics, 26, 841–842.


Smajić, S. et al. (2022) Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain, 145, 964–978.

Stuart, T. et al. (2020) Multimodal single-cell chromatin analysis with Signac Genomics.


Yang, D. et al. (2018) 3DIV: A 3D-genome Interaction Viewer and database. Nucleic Acids Research, 46, D52–D57.

Zhang,L. et al. (2016) Reconstructing directed gene regulatory network by only gene expression data. BMC Genomics, 17 Suppl 4, 430.


### **Supplementary Figures**




**Fig. S1. Strategy to compute the sign of the regulatory interactions.** The scRNA-seq dataset is used to compute the correlation between the TFs and genes of the GRN. TF-Gene interactions are directly signed using the correlation values. Enhancer-Promoter interactions are signed by summing the correlation values between the TFs binding to the enhancer and the regulated gene/promoter. TF-Enhancer interactions are signed by computing for each TF the sum of the correlation values between the TF and the genes regulated by the enhancer.




**Fig. S2. Comparison of the precision in the identification of gene-disease interactions between eQTL and RNetDys.** Ratio for the captured genes reported as linked to the disease according to OMIM is represented in y axis. Each boxplot represents ratios across all cell (sub)types for AD, EPI, PD, T1D and T2D.




**Fig. S3. Cell (sub)type specific regulatory impairment in PD.** Network visualization of impaired regulatory interactions for (A) astrocytes, (B) excitatory neurons, (C) dopaminergic neurons, (D) oligodendrocytes and (E) OPCs. TFs are represented as diamond in light red, enhancers as yellow rectangles and genes in blue rectangles. Arrows represent activations. The weight of edges from TFs correspond to the strength of the impairment, with the thinnest translating a strong lack of binding affinity and a large edge being a strong increase in binding affinity. The color of the edges from TFs represents the log2FC with green being a decreased affinity and red an increased one.




**Fig. S4. Cell (sub)type specific regulatory impairment in EPI.** Network visualization of impaired regulatory interactions for (A) astrocytes, (B) excitatory neurons, (C) inhibitory neurons, (D) microglia, (E) oligodendrocytes and (F) OPCs. TFs are represented as diamond in light red, enhancers as yellow rectangles and genes in blue rectangles. Arrows represent activations and T edges represent repressions. The weight of edges from TFs correspond to the strength of the impairment, with the thinnest translating a strong lack of binding affinity and a large edge being a strong increase in binding affinity. The color of the edges from TFs represents the log2FC with green being a decreased affinity and red an increased one.




**Fig. S5. Cell type specific impairment in T1D.** Network visualization of impaired regulatory interactions for (A) alpha cells and (B) beta and delta cells. TFs are represented as diamond in light red, enhancers as yellow rectangles and genes in blue rectangles. Arrows represent activations. The weight of edges from TFs correspond to the strength of the impairment, with the thinnest translating a strong lack of binding affinity and a large edge being a strong increase in binding affinity. The color of the edges from TFs represents the log2FC with green being a decreased affinity and red an increased one.



**Fig. S6. Cell type specific impairment in T2D.** Network visualization of impaired regulatory interactions for (A) alpha cells, (B) beta cells, (C) delta cells and (D) gamma cells. TFs are represented as diamond in light red, enhancers as yellow rectangles and genes in blue rectangles. Arrows represent activations. The weight of edges from TFs correspond to the strength of the impairment, with the thinnest translating a strong lack of binding affinity and a large edge being a strong increase in binding affinity. The color of the edges from TFs represents the log2FC with green being a decreased affinity and red an increased one.



**Fig. S7. Distribution of the outdegree ratio for specific TFs across cell (sub)types.** Histogram showing the frequency of outdegree ratios across all cell (sub)types for three TFs. The outdegree ratio of (A) MXI1, (B) CREB1, and (C) STAT3 in each specific cell (sub)type is represented by coloured vertical lines in the histograms. Astro: astrocytes, Ex: excitatory neurons, DAn: dopaminergic neurons, Inh: inhibitory neurons, Mic: microglia, Oligo: oligodendrocytes, OPCs: oligodendrocyte progenitors, Alpha: alpha cells, Beta: beta cells, Delta: delta cells, Gamma: gamma cells.



**Fig. S8. Threshold selection to define accessibility of promoter regions.** Delta probability between true positives and false positives. The peak of the distribution, equal to 0.48, corresponds to the highest probability to capture a true accessible promoter region in the cell (sub)type.

## **Supplementary Tables**

Accession Number	Cell line	Type of data	TF-Promoter benchmarking	Enhancer-Promoter benchmarking
GSE100344	BJ	scRNA-seq	Х	Х
GSE113415	BJ	scRNA-seq	Х	Х
GSE160910	BJ	scRNA-seq	Х	Х
GSE166935	BJ	scRNA-seq	Х	Х
scOpen*	BJ	scATAC-seq	Х	Х
GSE99172	BJ	scATAC-seq	Х	Х
GSE81861	GM12878	scRNA-seq	Х	Х
GSM3596321	GM12878	scRNA-seq	Х	Х
GSM4156602	GM12878	scRNA-seq	Х	Х
GSM4156603	GM12878	scRNA-seq	Х	Х
scOpen*	GM12878	scATAC-seq	Х	Х
GSE99172	GM12878	scATAC-seq	Х	Х
GSE64016	H1-ESC	scRNA-seq	Х	Х
GSE75748	H1-ESC	scRNA-seq	Х	Х
GSE81861	H1-ESC	scRNA-seq	Х	Х
GSM5534158	H1-ESC	scRNA-seq	Х	Х
scOpen*	H1-ESC	scATAC-seq	Х	Х
GSE99172	H1-ESC	scATAC-seq	Х	Х
GSE81861	A549	scRNA-seq	Х	

Table S1. Single cell datasets used for validation and comparison

GSM3271042	A549	scRNA-seq	X	
GSM3271043	A549	scATAC-seq	Х	
GSM4224433	A549	scATAC-seq	Х	
GSE105451	Jurkat	scRNA-seq	X	
10x platform**	Jurkat	scRNA-seq	Х	
GSE107816	Jurkat	scATAC-seq	X	
GSE81861	K562	scRNA-seq	Х	
GSE90063	K562	scRNA-seq	X	
GSE113415	K562	scRNA-seq	X	
GSM1599500	K562	scRNA-seq	X	
scOpen*	K562	scATAC-seq	Х	
GSE99172	K562	scATAC-seq	Х	

\*scOpen: https://github.com/CostaLab/scopen-reproducibility

\*\*10x platform: https://www.10xgenomics.com/resources/datasets/jurkat-cells-1-standard-1-1-0

### Table S2. Collected datasets to generate healthy cell (sub)type GRNs.

System	Accession	Type of data
Pancreas	GSE85241	scRNA-seq
Fancieas	GSM558939	scATAC-seq
	GSE157783 (Healthy)	scRNA-seq
Brain	GSE97942	scRNA-seq
	GSE147672	scATAC-seq

### Table S3. Matching of the scRNA-seq and scATAC-seq brain datasets.

scATAC-seq Brain Regions	scRNA-seq Brain Region Matched	Brain region abbreviation
Substantia Nigra	Human Midbrain (GSE157783, Healthy)	SUNI
Middle Frontal Gyrus	Frontal Cortex (GSE97942)	MDFG

### Table S4. Literature-based validation of the predicted impaired regulatory interactions.

PD							
			Cell	G	WAS	Cell type specific e-QTL*	
Source (TF or enhancer)	Gene	RSID	(sub)pop	SNP Linked to gene	PMID	SNP Linked to gene	
chr22:32473200-32478044	TIMP3	rs11538371	Astro			х	
chr22:32473200-32478044	TIMP3	rs2072814	Astro			х	
chr22:32473200-32478044	TIMP3	rs8137714	Astro			х	

chr4:41255600-41259401	UCHL1	rs5030732	DAn	х	28253266,	Х
STAT3	UCHL1	rs5030732	DAn	х	25370916, 22839974	x
NFKB1, STAT3	PRKAG2	rs117728810	DAn	x		х
NFKB1, STAT3	PRKAG2	rs66628686	DAn	x		х
STAT3	PRKAG2	rs77902041	DAn	х		х
chr4:41255600-41259401	UCHL1	rs11556273	Ex	x		х
chr4:41255600-41259401	UCHL1	rs5030732	Ex	х		х
chr4:41255600-41259401	UCHL1	rs9321	Ex	х		х
CREB1	UCHL1	rs11556273	Ex	х		х
chr22:32473200-32478044	FBXO7	rs2072814	Oligo	х		х
chr4:41255600-41259401	LIMCH1	rs5030732	Oligo			х
chr4:41255600-41259401	LIMCH1	rs9321	Oligo			х
chr22:32473200-32478044	FBXO7	rs11538371	OPCs	х		х
BCL6	FBXO7	rs11538371	OPCs	х		x
chr22:32473200-32478044	FBXO7	rs2072814	OPCs	х		x
chr22:32473200-32478044	FBXO7	rs8137714	OPCs	х	18513678	х
BCL6	FBXO7	rs8137714	OPCs	х	10515070	х
chr12:40222200-40227694	LRRK2	rs112643657	OPCs	х		
		A	D			
		A	D	G	WAS	Cell type
Source	Target	A RSID	D Pop		WAS	Cell type specific e-QTL*
Source	Target			G <sup>1</sup> Linked to gene	WAS PMID	
	<b>Target</b> PSEN1			Linked	PMID	specific e-QTL*
	-	RSID	Рор	Linked to gene		specific e-QTL* Linked to gene
chr14:73135401-73138601 STAT3	PSEN1	<b>RSID</b> rs1800839	<b>Pop</b> Astro	Linked to gene X	<b>PMID</b> 28821390, 11389157	specific e-QTL* Linked to gene x
chr14:73135401-73138601	PSEN1 PSEN1	<b>RSID</b> rs1800839 rs1800839	Pop Astro Astro	Linked to gene x x	<b>PMID</b> 28821390,	specific e-QTL* Linked to gene x
chr14:73135401-73138601 STAT3 chr21:26166164-26172001	PSEN1 PSEN1 APP	<b>RSID</b> rs1800839 rs1800839 rs45476095	Pop Astro Astro Astro	Linked to gene x x x	<b>PMID</b> 28821390, 11389157	specific e-QTL* Linked to gene x
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1	PSEN1 PSEN1 APP APP	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095	Pop Astro Astro Astro Astro	Linked to gene X X X X X X	<b>PMID</b> 28821390, 11389157	specific e-QTL* Linked to gene x
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1 chr14:73135401-73138601	PSEN1 PSEN1 APP APP APP	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095 rs459543	Pop Astro Astro Astro Astro Astro	Linked to gene X X X X X X X	PMID 28821390, 11389157 21654062 21654062, 16685645	specific e-QTL* Linked to gene x
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1 chr14:73135401-73138601 MXI1 chr14:73135401-73138601	PSEN1 PSEN1 APP APP APP APP PSEN1	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095 rs459543 rs459543 rs459543	Pop Astro Astro Astro Astro Astro Astro Ex	Linked to gene X X X X X X X X X	PMID 28821390, 11389157 21654062 21654062, 16685645 28821390,	specific e-QTL* Linked to gene x x
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1 chr14:73135401-73138601 MXI1 chr14:73135401-73138601 CREB1	PSEN1 PSEN1 APP APP APP APP PSEN1 PSEN1	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095 rs459543 rs459543 rs1800839 rs1800839	Pop Astro Astro Astro Astro Astro Astro Ex Ex	Linked to gene X X X X X X X X X X	PMID 28821390, 11389157 21654062 21654062, 16685645 28821390, 11389157	specific e-QTL* Linked to gene X X X
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1 chr14:73135401-73138601 MXI1 chr14:73135401-73138601	PSEN1 PSEN1 APP APP APP APP PSEN1	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095 rs459543 rs459543 rs459543	Pop Astro Astro Astro Astro Astro Astro Ex	Linked to gene X X X X X X X X X	PMID 28821390, 11389157 21654062 21654062, 16685645 28821390,	specific e-QTL* Linked to gene X X X
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1 chr14:73135401-73138601 MXI1 chr14:73135401-73138601 CREB1	PSEN1 PSEN1 APP APP APP APP PSEN1 PSEN1	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095 rs459543 rs459543 rs1800839 rs1800839	Pop Astro Astro Astro Astro Astro Astro Ex Ex	Linked to gene X X X X X X X X X X	PMID 28821390, 11389157 21654062 21654062, 16685645 28821390, 11389157	specific e-QTL* Linked to gene X X X
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1 chr14:73135401-73138601 MXI1 chr14:73135401-73138601 CREB1 chr21:26166164-26172001	PSEN1 PSEN1 APP APP APP APP PSEN1 PSEN1 APP	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095 rs459543 rs459543 rs1800839 rs1800839 rs1800839	Pop Astro Astro Astro Astro Astro Astro Ex Ex Ex	Linked to gene X X X X X X X X X X X	PMID 28821390, 11389157 21654062 21654062, 16685645 28821390, 11389157 21654062 21654062, 16685645	specific e-QTL* Linked to gene X X X
chr14:73135401-73138601 STAT3 chr21:26166164-26172001 MXI1 chr14:73135401-73138601 MXI1 chr14:73135401-73138601 CREB1 chr21:26166164-26172001 chr21:26166164-26172001	PSEN1 PSEN1 APP APP APP PSEN1 PSEN1 APP APP	<b>RSID</b> rs1800839 rs1800839 rs45476095 rs45476095 rs459543 rs459543 rs1800839 rs1800839 rs1800839 rs45476095 rs459543	Pop Astro Astro Astro Astro Astro Astro Ex Ex Ex Ex	Linked to gene X X X X X X X X X X X X X X X	PMID 28821390, 11389157 21654062 21654062, 16685645 28821390, 11389157 21654062 21654062,	specific e-QTL* Linked to gene X X X

	1	1			•	
chr21:26166164-26172001	APP	rs459543	Inh	x	21654062, 16685645	
chr21:26166164-26172001	APP	rs1800839	Mic			
chr21:26166164-26172001	APP	rs45476095	Mic	x	21654062	
chr14:73135401-73138601	APP	rs459543	Mic	х	21654062, 16685645	
CREB1	PSEN1	rs1800839	Oligo	х	28821390, 11389157	
chr21:26166164-26172001	APP	rs45476095	Oligo	х	21654062	
chr14:73135401-73138601	APP	rs459543	Oligo	x	21654062, 16685645	
chr14:73135401-73138601	PSEN1	rs1800839	OPCs	х		х
CREB1	PSEN1	rs1800839	OPCs	x	28821390, 11389157	х
chr21:26166164-26172001	APP	rs45476095	OPCs	х	11369137	
chr21:26166164-26172001	APP	rs459543	OPCs	x		
	<u>I</u>	E	PI	Į	<u> </u>	
				G	WAS	Cell type
Source	Target	RSID	P	U	WA5	specific e-QTL*
Source	Target	RSID	Рор	** * *		
Source	Target	RSID	Рор	Linked to gene	PMID	Linked to gene
chr5:126592200-	ALDH7A1	rs144272515	Pop	Linked to gene x	PMID	Linked to gene
				to gene	PMID	
chr5:126592200- 126596201	ALDH7A1	rs144272515	Astro	to gene x	PMID	x
chr5:126592200- 126596201 ZFX	ALDH7A1 ALDH7A1	rs144272515 rs144272515	Astro	to gene x x	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459	ALDH7A1 ALDH7A1 PRICKLE2	rs144272515 rs144272515 rs697287	Astro Astro Astro	to gene x x	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2	rs144272515 rs144272515 rs697287 rs900641	Astro Astro Astro Astro	to gene x x x x	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2	rs144272515 rs144272515 rs697287 rs900641 rs142388795	Astro Astro Astro Astro Astro	to gene X X X X X	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 sTAT3 chr5:126592200-	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795	Astro Astro Astro Astro Astro Astro	to gene X X X X X X X	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077	Astro Astro Astro Astro Astro Astro Astro	to gene x x x x x x x x x x	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201 STAT3 chr3:64223200-64226459 STAT3	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1 ALDH7A1	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077 rs146562077	Astro Astro Astro Astro Astro Astro Astro Astro	to gene x x x x x x x x x x x	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201 STAT3 chr3:64223200-64226459	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1 ALDH7A1 PRICKLE2	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077 rs146562077 rs150393747	Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro	to gene X X X X X X X X X X X	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201 STAT3 chr3:64223200-64226459 STAT3 chr3:64223200-64226459	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077 rs146562077 rs150393747 rs150393747	Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro	to gene x x x x x x x x x x x x x x x x	PMID	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201 STAT3 chr3:64223200-64226459 STAT3 chr6:145733617- 145737579	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 EPM2A	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077 rs146562077 rs150393747 rs150393747 rs2235482	Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro	to gene x x x x x x x x x x x x x x x x x	PMID 11735300	x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201 STAT3 chr3:64223200-64226459 STAT3 chr6:145733617- 145737579 BCL6, STAT3, ZFX chr6:145733617-	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 EPM2A EPM2A	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077 rs146562077 rs150393747 rs150393747 rs2235482 rs2235482	Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro	to gene		x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201 STAT3 chr3:64223200-64226459 STAT3 chr3:64223200-64226459 STAT3 chr6:145733617- 145737579 BCL6, STAT3, ZFX chr6:145733617- 145737579 BCL6 chr5:126592200- 126596201	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 EPM2A EPM2A EPM2A	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077 rs146562077 rs150393747 rs150393747 rs2235482 rs2235482 rs2235482	Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro	to gene   X		x x
chr5:126592200- 126596201 ZFX chr3:64223200-64226459 chr3:64223200-64226459 chr3:64223200-64226459 STAT3 chr5:126592200- 126596201 STAT3 chr3:64223200-64226459 STAT3 chr6:145733617- 145737579 BCL6, STAT3, ZFX chr6:145733617- 145737579 BCL6 chr5:126592200-	ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 PRICKLE2 ALDH7A1 ALDH7A1 PRICKLE2 PRICKLE2 PRICKLE2 EPM2A EPM2A EPM2A EPM2A	rs144272515 rs144272515 rs697287 rs900641 rs142388795 rs142388795 rs146562077 rs146562077 rs150393747 rs150393747 rs2235482 rs2235482 rs2235482 rs374338349 rs374338349	Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro Astro	to gene   X		x x

chr5:126592200-	ALDH7A1	rs900640	Astro	х		
126596201 STAT3	ALDH7A1	rs900640	Astro	х		
ZFX	ALDH7A1	rs900640	Astro	X		
chr3:64223200-64226459	PRICKLE2	rs697287	Ex			v
CIII 3.04223200-04220433	I KICKLEZ	18097287	EX	х		Х
CREB1	GABRB3	rs20317	Ex	х	30074174, 24999380, 25025424	х
CREB1	KCTD7	rs117194263	Ex	x		
chr3:64223200-64226459	PRICKLE2	rs142388795	Ex	х		
CREB1	PRICKLE2	rs142388795	Ex	х		
chr7:66625550-66632156	KCTD7	rs35526611	Ex	х		
CREB1	KCTD7	rs35526611	Ex	х		
CREB1	GABRB3	rs20317	Inh	x	30074174, 24999380, 25025424	Х
CREB1	KCTD7	rs117194263	Inh	х		
CREB1, STAT3	PRICKLE2	rs142388795	Inh	х		
STAT3	PRICKLE2	rs150393747	Inh	х		
MXI1	KCNC1	rs2229007	Inh	х		
chr7:66625550-66632156	KCTD7	rs35526611	Inh	х		
CREB1	KCTD7	rs35526611	Inh	х		
STAT3	CACNB4	rs61736804	Inh	х		
STAT1	SCARB2	rs72857097	Inh	х		
STAT3	KCTD7	rs77341088	Inh	х		
chrX:47619001-47620600	SYN1	rs187134574	Inh	х		No data on chrX
STAT3	SYN1	rs187134574	Inh	x		No data on chrX
CREB1	KCTD7	rs117194263	Mic	x		
chr4:122920756- 122924601	SPATA5	rs35430470	Mic	х		
chr7:66625550-66632156	KCTD7	rs35526611	Mic	х		
CREB1	KCTD7	rs35526611	Mic	x		
CREB1	KCTD7	rs117194263	Oligo	x		
CREB1	GABRB3	rs20317	Oligo	x	30074174, 24999380, 25025424	
chr7:66625550-66632156	KCTD7	rs35526611	Oligo	х		
CREB1	KCTD7	rs35526611	Oligo	х		
CREB1	RBFOX1	rs7187508	Oligo	х		
chr3:64223200-64226459	PRICKLE2	rs697287	OPCs	x		Х
CREB1	KCTD7	rs117194263	OPCs	x		
chr3:64223200-64226459	PRICKLE2	rs142388795	OPCs	х		

Source	Target	RSID	Рор	G	WAS	specific e-QTL
		T2	2D			Cell type
STAT3	KCNJ11	rs5210	Delta	X	32693412, 33101408, 30641791	
CREB1, STAT3	KCNJ11	rs41282930	Delta	х	25247988, 22289434, 15115830	
STAT3	KCNJ11	rs2285676	Delta	x	32930968, 29903275, 27249660	
CREB1, STAT3	KCNJ11	rs1800467	Delta	x	25733456, 26937418, 25247988	
STAT3	KCNJ11	rs5210	Beta	x	32693412, 33101408, 30641791	No data
CREB1, STAT3	KCNJ11	rs41282930	Beta	x	25247988, 22289434, 15115830	
STAT3	KCNJ11	rs2285676	Beta	x	32930968, 29903275, 27249660	
CREB1, STAT3	KCNJ11	rs1800467	Beta	x	25733456, 26937418, 25247988	
chr20:44397802-44420654	TTPAL	rs736823	Alpha			
chr20:44397802-44420654	TTPAL	rs1800961	Alpha			
chr20:44397802-44420654	TTPAL	rs113308087	Alpha	to gene		
Source	Target	RSID	Рор	Linked	WAS PMID	Cell type specific e-QTL Linked to gene
	I	T1	ID	1		Call from a
chr12:42468600-42471319	PRICKLE1	rs74081707	OPCs	х		
STAT1	SCARB2	rs72857097	OPCs	х		
chr4:76205669-76215919	SCARB2	rs72857097	OPCs	х		
CREB1	RBFOX1	rs7187508	OPCs	x	21698661	
CREB1	SCN9A	rs4369876	OPCs	х	23292638,	
CREB1	KCTD7	rs35526611	OPCs	x		
CREB1 chr7:66625550-66632156	PRICKLE2 KCTD7	rs142388795 rs35526611	OPCs OPCs	x x		

				Linked to gene	PMID	Linked to gene
chr20:44397802-44420654	TTPAL	rs113308087	Alpha	8		
chr20:44397802-44420654	TTPAL	rs1169288	Alpha			
chr12:120977075- 120985314	ANAPC5	rs1169289	Alpha			
chr20:45334860-45349300	PIGT	rs147593522	Alpha			
STAT3	ABCC8	rs1799859	Alpha	x	28587604, 26740944	
chr20:44397802-44420654	TTPAL	rs1800961	Alpha			
chr4:26318200-26324401	RBPJ	rs186895314	Alpha	х		
chr20:44397802-44420654	TTPAL	rs2072792	Alpha			No data
ATF2	RBPJ	rs73245775	Alpha	х		
STAT3	ABCC8	rs757110	Alpha	х	32660410, 32468916, 32930968	
chr20:45334860-45349300	SYS1	rs147593522	Beta			
PDX1, STAT3	ABCC8	rs1799859	Beta	х	28587604, 26740944	
chr4:26318200-26324401	RBPJ	rs186895314	Beta	х		
chr20:45334860-45349300	SYS1	rs2072792	Beta			

\*https://zenodo.org/record/6104982#.Yq2eUy0RryY